학술논문
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
Document Type
Article
Author
Source
In: Gynecologic Oncology . (Gynecologic Oncology, March 2024, 182:124-131)
Subject
Language
English
ISSN
10956859
00908258
00908258